Chapter 1: Introduction
 1.1 Research Objectives
 1.2 Research Methodology
 1.3 Research Process
 1.4 Scope and Coverage
  1.4.1 Market Definition
  1.4.2 Key Questions Answered
 1.5 Market Segmentation

Chapter 2:Executive Summary

Chapter 3:Growth Opportunities By Segment
 3.1 By Type
 3.2 By Application

Chapter 4: Market Landscape
 4.1 Porter's Five Forces Analysis
  4.1.1 Bargaining Power of Supplier
  4.1.2 Threat of New Entrants
  4.1.3 Threat of Substitutes
  4.1.4 Competitive Rivalry
  4.1.5 Bargaining Power Among Buyers
 4.2 Industry Value Chain Analysis
 4.3 Market Dynamics
  4.3.1 Drivers
  4.3.2 Restraints
  4.3.3 Opportunities
  4.5.4 Challenges
 4.4 Pestle Analysis
 4.5 Technological Roadmap
 4.6 Regulatory Landscape
 4.7 SWOT Analysis
 4.8 Price Trend Analysis
 4.9 Patent Analysis
 4.10 Analysis of the Impact of Covid-19
  4.10.1 Impact on the Overall Market
  4.10.2 Impact on the Supply Chain
  4.10.3 Impact on the Key Manufacturers
  4.10.4 Impact on the Pricing

Chapter 5: Antisense ODN Market by Type
 5.1 Antisense ODN Market Overview Snapshot and Growth Engine
 5.2 Antisense ODN Market Overview
 5.3 With Chemical Modification
  5.3.1 Introduction and Market Overview
  5.3.2 Historic and Forecasted Market Size (2017-2032F)
  5.3.3 Key Market Trends, Growth Factors and Opportunities
  5.3.4 With Chemical Modification: Geographic Segmentation
 5.4 Without Chemical Modification
  5.4.1 Introduction and Market Overview
  5.4.2 Historic and Forecasted Market Size (2017-2032F)
  5.4.3 Key Market Trends, Growth Factors and Opportunities
  5.4.4 Without Chemical Modification: Geographic Segmentation

Chapter 6: Antisense ODN Market by Application
 6.1 Antisense ODN Market Overview Snapshot and Growth Engine
 6.2 Antisense ODN Market Overview
 6.3 Neuromuscular Diseases
  6.3.1 Introduction and Market Overview
  6.3.2 Historic and Forecasted Market Size (2017-2032F)
  6.3.3 Key Market Trends, Growth Factors and Opportunities
  6.3.4 Neuromuscular Diseases: Geographic Segmentation
 6.4 hATTR
  6.4.1 Introduction and Market Overview
  6.4.2 Historic and Forecasted Market Size (2017-2032F)
  6.4.3 Key Market Trends, Growth Factors and Opportunities
  6.4.4 hATTR: Geographic Segmentation
 6.5 Other
  6.5.1 Introduction and Market Overview
  6.5.2 Historic and Forecasted Market Size (2017-2032F)
  6.5.3 Key Market Trends, Growth Factors and Opportunities
  6.5.4 Other: Geographic Segmentation

Chapter 7: Company Profiles and Competitive Analysis
 7.1 Competitive Landscape
  7.1.1 Competitive Positioning
  7.1.2 Antisense ODN Sales and Market Share By Players
  7.1.3 Industry BCG Matrix
  7.1.4 Heat Map Analysis
  7.1.5 Antisense ODN Industry Concentration Ratio (CR5 and HHI)
  7.1.6 Top 5 Antisense ODN Players Market Share
  7.1.7 Mergers and Acquisitions
  7.1.8 Business Strategies By Top Players
 7.2 SAREPTA THERAPEUTICS
  7.2.1 Company Overview
  7.2.2 Key Executives
  7.2.3 Company Snapshot
  7.2.4 Operating Business Segments
  7.2.5 Product Portfolio
  7.2.6 Business Performance
  7.2.7 Key Strategic Moves and Recent Developments
  7.2.8 SWOT Analysis
 7.3 IONIS PHARMACEUTICALS
 7.4 BIOGEN
 7.5 NIPPON SHINYAKU
 7.6 SOBI
 7.7 JAZZ PHARMACEUTICALS

Chapter 8: Global Antisense ODN Market Analysis, Insights and Forecast, 2017-2032
 8.1 Market Overview
 8.2 Historic and Forecasted Market Size By Type
  8.2.1 With Chemical Modification
  8.2.2 Without Chemical Modification
 8.3 Historic and Forecasted Market Size By Application
  8.3.1 Neuromuscular Diseases
  8.3.2 hATTR
  8.3.3 Other

Chapter 9: North America Antisense ODN Market Analysis, Insights and Forecast, 2017-2032
 9.1 Key Market Trends, Growth Factors and Opportunities
 9.2 Impact of Covid-19
 9.3 Key Players
 9.4 Key Market Trends, Growth Factors and Opportunities
 9.4 Historic and Forecasted Market Size By Type
  9.4.1 With Chemical Modification
  9.4.2 Without Chemical Modification
 9.5 Historic and Forecasted Market Size By Application
  9.5.1 Neuromuscular Diseases
  9.5.2 hATTR
  9.5.3 Other
 9.6 Historic and Forecast Market Size by Country
  9.6.1 US
  9.6.2 Canada
  9.6.3 Mexico

Chapter 10: Eastern Europe Antisense ODN Market Analysis, Insights and Forecast, 2017-2032
 10.1 Key Market Trends, Growth Factors and Opportunities
 10.2 Impact of Covid-19
 10.3 Key Players
 10.4 Key Market Trends, Growth Factors and Opportunities
 10.4 Historic and Forecasted Market Size By Type
  10.4.1 With Chemical Modification
  10.4.2 Without Chemical Modification
 10.5 Historic and Forecasted Market Size By Application
  10.5.1 Neuromuscular Diseases
  10.5.2 hATTR
  10.5.3 Other
 10.6 Historic and Forecast Market Size by Country
  10.6.1 Bulgaria
  10.6.2 The Czech Republic
  10.6.3 Hungary
  10.6.4 Poland
  10.6.5 Romania
  10.6.6 Rest of Eastern Europe

Chapter 11: Western Europe Antisense ODN Market Analysis, Insights and Forecast, 2017-2032
 11.1 Key Market Trends, Growth Factors and Opportunities
 11.2 Impact of Covid-19
 11.3 Key Players
 11.4 Key Market Trends, Growth Factors and Opportunities
 11.4 Historic and Forecasted Market Size By Type
  11.4.1 With Chemical Modification
  11.4.2 Without Chemical Modification
 11.5 Historic and Forecasted Market Size By Application
  11.5.1 Neuromuscular Diseases
  11.5.2 hATTR
  11.5.3 Other
 11.6 Historic and Forecast Market Size by Country
  11.6.1 Germany
  11.6.2 UK
  11.6.3 France
  11.6.4 Netherlands
  11.6.5 Italy
  11.6.6 Russia
  11.6.7 Spain
  11.6.8 Rest of Western Europe

Chapter 12: Asia Pacific Antisense ODN Market Analysis, Insights and Forecast, 2017-2032
 12.1 Key Market Trends, Growth Factors and Opportunities
 12.2 Impact of Covid-19
 12.3 Key Players
 12.4 Key Market Trends, Growth Factors and Opportunities
 12.4 Historic and Forecasted Market Size By Type
  12.4.1 With Chemical Modification
  12.4.2 Without Chemical Modification
 12.5 Historic and Forecasted Market Size By Application
  12.5.1 Neuromuscular Diseases
  12.5.2 hATTR
  12.5.3 Other
 12.6 Historic and Forecast Market Size by Country
  12.6.1 China
  12.6.2 India
  12.6.3 Japan
  12.6.4 South Korea
  12.6.5 Malaysia
  12.6.6 Thailand
  12.6.7 Vietnam
  12.6.8 The Philippines
  12.6.9 Australia
  12.6.10 New Zealand
  12.6.11 Rest of APAC

Chapter 13: Middle East & Africa Antisense ODN Market Analysis, Insights and Forecast, 2017-2032
 13.1 Key Market Trends, Growth Factors and Opportunities
 13.2 Impact of Covid-19
 13.3 Key Players
 13.4 Key Market Trends, Growth Factors and Opportunities
 13.4 Historic and Forecasted Market Size By Type
  13.4.1 With Chemical Modification
  13.4.2 Without Chemical Modification
 13.5 Historic and Forecasted Market Size By Application
  13.5.1 Neuromuscular Diseases
  13.5.2 hATTR
  13.5.3 Other
 13.6 Historic and Forecast Market Size by Country
  13.6.1 Turkey
  13.6.2 Bahrain
  13.6.3 Kuwait
  13.6.4 Saudi Arabia
  13.6.5 Qatar
  13.6.6 UAE
  13.6.7 Israel
  13.6.8 South Africa

Chapter 14: South America Antisense ODN Market Analysis, Insights and Forecast, 2017-2032
 14.1 Key Market Trends, Growth Factors and Opportunities
 14.2 Impact of Covid-19
 14.3 Key Players
 14.4 Key Market Trends, Growth Factors and Opportunities
 14.4 Historic and Forecasted Market Size By Type
  14.4.1 With Chemical Modification
  14.4.2 Without Chemical Modification
 14.5 Historic and Forecasted Market Size By Application
  14.5.1 Neuromuscular Diseases
  14.5.2 hATTR
  14.5.3 Other
 14.6 Historic and Forecast Market Size by Country
  14.6.1 Brazil
  14.6.2 Argentina
  14.6.3 Rest of SA

Chapter 15 Investment Analysis

Chapter 16 Analyst Viewpoint and Conclusion

Antisense ODN Scope:

Report Data	Antisense ODN Market
Antisense ODN Market Size in 2022	USD 4141.2 million
Antisense ODN CAGR 2023 - 2030	3.3%
Antisense ODN Base Year	2022
Antisense ODN Forecast Data	2023 - 2030
Segments Covered	By Type, By Application, And by Regions
Regional Scope	North America, Europe, Asia Pacific, Latin America, and Middle East & Africa
Key Companies Profiled	Sarepta Therapeutics, Ionis Pharmaceuticals, Biogen, Nippon Shinyaku, Sobi, Jazz Pharmaceuticals.
Key Segments	By Type With Chemical Modification Without Chemical Modification By Applications Neuromuscular Diseases hATTR Other